214 related articles for article (PubMed ID: 23519568)
1. Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia.
Ahn S; Lee YS; Lim KS; Lee JL
Support Care Cancer; 2013 Aug; 21(8):2303-8. PubMed ID: 23519568
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Serum Procalcitonin Levels in Patients With Febrile Neutropenia Presenting to the Emergency Department.
Yadav S; Mathew R; Sahu AK; Jamshed N; Mohindra R; Aggarwal P; Batra A; Halder D; Brunda RL
J Emerg Med; 2021 May; 60(5):641-647. PubMed ID: 33518374
[TBL] [Abstract][Full Text] [Related]
3. Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1beta, -6, -8 and -10.
Uys A; Rapoport BL; Fickl H; Meyer PW; Anderson R
Eur J Cancer Care (Engl); 2007 Nov; 16(6):475-83. PubMed ID: 17944761
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic performance of serum high-sensitivity procalcitonin and serum C-reactive protein tests for detecting bacterial infection in febrile neutropenia.
Aimoto M; Koh H; Katayama T; Okamura H; Yoshimura T; Koh S; Nanno S; Nishimoto M; Hirose A; Nakamae M; Nakane T; Nakamae H; Kakeya H; Hino M
Infection; 2014 Dec; 42(6):971-9. PubMed ID: 25038889
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of procalcitonin and lipopolysaccharide binding protein in cancer patients with chemotherapy-associated febrile neutropenia presenting to an emergency department.
García de Guadiana-Romualdo L; Cerezuela-Fuentes P; Español-Morales I; Esteban-Torrella P; Jiménez-Santos E; Hernando-Holgado A; Albaladejo-Otón MD
Biochem Med (Zagreb); 2019 Feb; 29(1):010702. PubMed ID: 30591812
[TBL] [Abstract][Full Text] [Related]
6. The role of procalcitonin in identifying high-risk cancer patients with febrile neutropenia: A useful alternative to the multinational association for supportive care in cancer score.
Chaftari P; Chaftari AM; Hachem R; Yeung SJ; Dagher H; Jiang Y; Malek AE; Dailey Garnes N; Mulanovich VE; Raad I
Cancer Med; 2021 Dec; 10(23):8475-8482. PubMed ID: 34725958
[TBL] [Abstract][Full Text] [Related]
7. [Significance of Procalcitonin Measurement in Cases with Febrile Condition during Chemotherapy for Urological Cancer].
Kurimura Y; Takahashi S; Hiyama Y; Uehara T; Ichihara K; Hashimoto J; Nishiyama N; Kitamura H; Masumori N
Hinyokika Kiyo; 2015 Apr; 61(4):141-5. PubMed ID: 26037672
[TBL] [Abstract][Full Text] [Related]
8. Impact of time to antibiotics on outcomes of chemotherapy-induced febrile neutropenia.
Ko BS; Ahn S; Lee YS; Kim WY; Lim KS; Lee JL
Support Care Cancer; 2015 Sep; 23(9):2799-804. PubMed ID: 25663578
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents.
Ahn S; Rice TW; Yeung SJ; Cooksley T
Support Care Cancer; 2018 May; 26(5):1465-1470. PubMed ID: 29168032
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors of bacteraemia in low-risk patients with febrile neutropenia.
Ahn S; Lee YS; Chun YH; Lim KS; Kim W; Lee JL
Emerg Med J; 2012 Sep; 29(9):715-9. PubMed ID: 22011971
[TBL] [Abstract][Full Text] [Related]
11. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.
Innes H; Lim SL; Hall A; Chan SY; Bhalla N; Marshall E
Support Care Cancer; 2008 May; 16(5):485-91. PubMed ID: 17899215
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of the Multinational Association of Supportive Care in Cancer (MASCC) and Clinical Index of Stable Febrile Neutropenia (CISNE) scores for predicting serious complications in adult patients with febrile neutropenia: A systematic review and meta-analysis.
Zheng B; Toarta C; Cheng W; Taljaard M; Reaume N; Perry JJ
Crit Rev Oncol Hematol; 2020 May; 149():102922. PubMed ID: 32244162
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic accuracy of lipopolysaccharide-binding protein for predicting bacteremia/clinical sepsis in children with febrile neutropenia: comparison with interleukin-6, procalcitonin, and C-reactive protein.
Kitanovski L; Jazbec J; Hojker S; Derganc M
Support Care Cancer; 2014 Jan; 22(1):269-77. PubMed ID: 24057110
[TBL] [Abstract][Full Text] [Related]
14. Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia.
Jimeno A; García-Velasco A; del Val O; González-Billalabeitia E; Hernando S; Hernández R; Sánchez-Muñoz A; López-Martín A; Durán I; Robles L; Cortés-Funes H; Paz-Ares L
Cancer; 2004 Jun; 100(11):2462-9. PubMed ID: 15160353
[TBL] [Abstract][Full Text] [Related]
15. Management of febrile neutropenia in malignancy using the MASCC score and other factors: Feasibility and safety in routine clinical practice.
Kumar P; Bajpai J; Shetty N; Medekar A; Kurkure PA; Ghadyalpatil N; Gupta S; Noronha V; Kanujia A; Parikh P; Banavali SD
Indian J Cancer; 2014; 51(4):491-5. PubMed ID: 26842174
[TBL] [Abstract][Full Text] [Related]
16. IL-10 combined with procalcitonin improves early prediction of complications of febrile neutropenia in hematological patients.
Vänskä M; Koivula I; Jantunen E; Hämäläinen S; Purhonen AK; Pulkki K; Juutilainen A
Cytokine; 2012 Dec; 60(3):787-92. PubMed ID: 22902948
[TBL] [Abstract][Full Text] [Related]
17. Procalcitonin in febrile neutropenia--timing is important.
Tan BH; Png ME; Yeo CP; Wong GC
Support Care Cancer; 2014 Mar; 22(3):583-4. PubMed ID: 24306056
[No Abstract] [Full Text] [Related]
18. CISNE versus MASCC: Identifying low risk febrile neutropenic patients.
Mohindra R; Mathew R; Yadav S; Aggarwal P
Am J Emerg Med; 2020 Nov; 38(11):2259-2263. PubMed ID: 31864874
[TBL] [Abstract][Full Text] [Related]
19. [Modalities of management of cancer patients with febrile neutropenia in the oncology emergency unit of Gustave-Roussy and their related costs].
Borget I; Antoun S; Chachaty E; Gachot B; Alibay A; Di Palma M; Merad M
Bull Cancer; 2014 Oct; 101(10):925-31. PubMed ID: 25373692
[TBL] [Abstract][Full Text] [Related]
20. Can MASCC and CISNE scores predict delays of lung cancer chemotherapy after febrile neutropenia?
Ono Y; Hayama N; Hattori S; Ito Y; Oguma T; Sakamaki F; Asano K
Thorac Cancer; 2022 Dec; 13(24):3504-3509. PubMed ID: 36330990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
